Drugs / ProHema-CB
ProHema-CB
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT02354443 | Jun 2015 → Dec 2016 | inborn errors of metabolism | Fate Therapeutics | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT02354417 | Dec 2014 → Dec 2016 | hematopoietic and lymphoid cell neoplasm | Fate Therapeutics | Terminated | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01627314 | Jul 2012 → Mar 2016 | hematopoietic and lymphoid system neoplasm | Fate Therapeutics | Terminated | No outcome recorded Stop: Business |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2014-12-18 | Fate Therapeutics | Results Fate Therapeutics Announces Interim Data From Ongoing Phase 2 PUMA Study fatetherapeutics.com ↗
These early data showed that subjects administered PROHEMA, the Company's lead ex vivo programmed hematopoietic cellular therapeutic derived from umbilical cord blood, had an improved median time of neutrophil engraftment and an increased incidence of early neutrophil engraftment. |
| 2014-12-08 | Fate Therapeutics | Results Fate Therapeutics Highlights Effects of Nutrient-Rich Media on Ex Vivo Programmed CD34+ Cells Sourced From Umbilical Cord Blood fatetherapeutics.com ↗
Additionally, ex vivo programmed CD34+ cells exhibited a more than two-fold improvement in HSC engraftment in a xeno-transplantation study in NSG mice at 12-weeks post-transplant. |
| 2011-12-13 | Fate Therapeutics | Results Fate Therapeutics Announces Promising Data From Phase 1B Study of ProHema at the 2011 American Society of Hematology Annual Conference fatetherapeutics.com ↗
Fate Therapeutics, Inc. announced today promising clinical results from a Phase 1b trial of ProHema (FT1050-enhanced umbilical cord blood) as part of double-umbilical cord blood (UCB) transplants in adult patients with hematologic malignancies who have undergone reduced-intensity conditioning therapy. |
All press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2014-12-18 | Fate Therapeutics | Fate Therapeutics Announces Interim Data From Ongoing Phase 2 PUMA Study fatetherapeutics.com ↗ |
| 2014-12-08 | Fate Therapeutics | Fate Therapeutics Highlights Effects of Nutrient-Rich Media on Ex Vivo Programmed CD34+ Cells Sourced From Umbilical Cord Blood fatetherapeutics.com ↗ |
| 2011-12-13 | Fate Therapeutics | Fate Therapeutics Announces Promising Data From Phase 1B Study of ProHema at the 2011 American Society of Hematology Annual Conference fatetherapeutics.com ↗ |
| 2011-02-21 | Fate Therapeutics | Fate Therapeutics Announces Emerging Data From Proof-Of-Concept FT1050 Clinical Trial and Receives Orphan Drug Designation fatetherapeutics.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ProHema-CB | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02354417 ↗ |
| Known as | 16,16-dimethyl prostaglandin E2 | “ProHema-CB (the prostaglandin derivative, 16,16-dimethyl prostaglandin E2 also referred to as FT1050)” NCT02354417 ↗ |
| Known as | FT1050 | “ProHema-CB (the prostaglandin derivative, 16,16-dimethyl prostaglandin E2 also referred to as FT1050)” NCT02354417 ↗ |
| Modality | Cell therapy | “Ex-vivo CXCR4 upregulated hematopoietic progenitor cells, cord blood” NCT01627314 ↗ |